dc.contributor.author | West, EJ | |
dc.contributor.author | Scott, KJ | |
dc.contributor.author | Tidswell, E | |
dc.contributor.author | Bendjama, K | |
dc.contributor.author | Stojkowitz, N | |
dc.contributor.author | Lusky, M | |
dc.contributor.author | Kurzawa, M | |
dc.contributor.author | Prasad, R | |
dc.contributor.author | Toogood, G | |
dc.contributor.author | Ralph, C | |
dc.contributor.author | Anthoney, DA | |
dc.contributor.author | Melcher, AA | |
dc.contributor.author | Collinson, FJ | |
dc.contributor.author | Samson, A | |
dc.coverage.spatial | Switzerland | |
dc.date.accessioned | 2022-08-31T14:28:59Z | |
dc.date.available | 2022-08-31T14:28:59Z | |
dc.date.issued | 2022-04-27 | |
dc.identifier | ARTN 2181 | |
dc.identifier | cancers14092181 | |
dc.identifier.citation | Cancers, 2022, 14 (9), pp. 2181 - | en_US |
dc.identifier.issn | 2072-6694 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5355 | |
dc.identifier.eissn | 2072-6694 | |
dc.identifier.eissn | 2072-6694 | |
dc.identifier.doi | 10.3390/cancers14092181 | |
dc.description.abstract | Pexa-Vec is an engineered Wyeth-strain vaccinia oncolytic virus (OV), which has been tested extensively in clinical trials, demonstrating enhanced cytotoxic T cell infiltration into tumours following treatment. Favourable immune consequences to Pexa-Vec include the induction of an interferon (IFN) response, followed by inflammatory cytokine/chemokine secretion. This promotes tumour immune infiltration, innate and adaptive immune cell activation and T cell priming, culminating in targeted tumour cell killing, i.e., an immunologically 'cold' tumour microenvironment is transformed into a 'hot' tumour. However, as with all immunotherapies, not all patients respond in a uniformly favourable manner. Our study herein, shows a differential immune response by patients to intravenous Pexa-Vec therapy, whereby some patients responded to the virus in a typical and expected manner, demonstrating a significant IFN induction and subsequent peripheral immune activation. However, other patients experienced a markedly subdued immune response and appeared to exhibit an exhausted phenotype at baseline, characterised by higher baseline immune checkpoint expression and regulatory T cell (Treg) levels. This differential baseline immunological profile accurately predicted the subsequent response to Pexa-Vec and may, therefore, enable the development of predictive biomarkers for Pexa-Vec and OV therapies more widely. If confirmed in larger clinical trials, these immunological biomarkers may enable a personalised approach, whereby patients with an exhausted baseline immune profile are treated with immune checkpoint blockade, with the aim of reversing immune exhaustion, prior to or alongside OV therapy. | |
dc.format | Electronic | |
dc.format.extent | 2181 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.relation.ispartof | Cancers | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | biomarkers | |
dc.subject | differential immune response | |
dc.subject | immune checkpoint blockade | |
dc.subject | immune exhaustion | |
dc.subject | immunotherapy | |
dc.subject | interferon response | |
dc.subject | oncolytic virus therapy | |
dc.subject | vaccinia virus | |
dc.title | Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-04-15 | |
dc.date.updated | 2022-08-31T14:28:09Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.3390/cancers14092181 | en_US |
rioxxterms.licenseref.startdate | 2022-04-27 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35565310 | |
pubs.issue | 9 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy/Translational Immunotherapy (TL) | |
pubs.organisational-group | /ICR/ImmNet | |
pubs.publication-status | Published online | |
pubs.volume | 14 | |
icr.researchteam | Trans Immunotherapy | en_US |
dc.contributor.icrauthor | Melcher, Alan | |
icr.provenance | Deposited by Mr Arek Surman on 2022-08-31. Deposit type is initial. No. of files: 1. Files: Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients.pdf | |